3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
2
Completed
2
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Acute
1
Gastrointestinal Stromal Tumors
1
GIST
1
Interventions
asciminib
4
ponatinib
2
nilotinib
2
Dasatinib
2
pegylated granulocyte colony-stimulating factor
1
olverembatinib
1
letermovir
1
fludarabine phosphate
1
decitabine and cedazuridine drug combination
1
bosutinib
1
Whole-Body Irradiation
1
Stem Cell Transplantation
1
Specimen Handling
1
Rituximab
1
Practice Management, Medical
1
Positron-Emission Tomography
1
Melphalan
1
Interviews as Topic
1
Imatinib Mesylate
1
Drug Monitoring
1
Cyclophosphamide
1
Cord Blood Stem Cell Transplantation
1
Clofarabine
1
CT-P10
1
Busulfan
1
Bone Marrow Purging
1
Blood Component Removal
1
Antilymphocyte Serum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Leukemia, Myeloid, Chronic-Phase
×
olverembatinib
×
Clear all
NCT06423911
2025-06-03
POLARIS-2
Ascentage Pharma Group Inc.
Phase 3
Recruiting
285 enrolled